2027 ICD-10-CM Diagnosis Code C7B.00Secondary carcinoid tumors, unspecified site
ICD-10-CM Codes›C00–D49›C7B›C7B
- Billable — Valid for Submission
- Risk Adjusts — HCC 17
- Chronic Condition
C7B.00 is a billable ICD-10-CM diagnosis code for secondary carcinoid tumors, unspecified site. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 826 through 830, 843 through 845. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Malignant neuroendocrine tumors.
For Medicare Advantage risk adjustment, C7B.00 maps to CMS-HCC Category 17 (Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic) under the V28 model, adding a risk factor of about 4.209 for a community, non-dual, aged beneficiary in payment year 2027.
Code Identity
Code Classification
Medicare Risk Adjustment (HCC)Billing
C7B.00 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2027.
Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.
Instructional NotesGuidance
Instructions from the official ICD-10-CM Tabular List that apply to C7B.00: its own notes plus those printed at C7B and Chapter 2. A note printed at a category, block or chapter applies to every code under it.
Use Additional Code
Add a second code, after this one, to fully describe the condition.
- code to identify any functional activity
Notes
General instructions on how these codes are used.
- Functional activity
- All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
- Morphology [Histology]
- Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
- Primary malignant neoplasms overlapping site boundaries
- A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
- Malignant neoplasm of ectopic tissue
- Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
Source: CMS ICD-10-CM Tabular List. How to read instructional notes.
Referenced in Other NotesGuidance
Instructional notes printed at other codes that name C7B.00, its category, or a range that includes it.
Excludes1 2
These codes carry an Excludes1 note naming C7B.00: they are not reported together with it, unless the two conditions are unrelated.
Index to Diseases and InjuriesGuidance
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Metastatic Neuroendocrine Tumor
a neuroendocrine tumor that has spread from its original site of growth to another anatomic site.
Patient EducationClinical
Carcinoid Tumors
Carcinoid tumors are rare, slow-growing cancers. They usually start in the lining of the digestive tract or in the lungs. They grow slowly and don't produce symptoms in the early stages. As a result, the average age of people diagnosed with digestive or lung carcinoids is about 60.
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert C7B.00 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About C7B.00Overview
What is the ICD-10 code for secondary carcinoid tumors, unspecified site?
The ICD-10-CM code for secondary carcinoid tumors, unspecified site is C7B.00 (sometimes written as C7B00). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
Is C7B.00 (Secondary carcinoid tumors) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report secondary carcinoid tumors, unspecified site on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
What MS-DRG does C7B.00 group to?
When secondary carcinoid tumors, unspecified site is the principal diagnosis on an inpatient stay, it groups to MS-DRG 844, 827, 829, 843, 828, 826, 830, 845, with relative weights from 0.8443 to 4.7560 depending on complications. Higher weights mean higher Medicare reimbursement.
Does C7B.00 need an additional code?
When the condition applies, yes. The Use Additional Code note at C7B, which applies to C7B.00, reads: code to identify any functional activity. The additional code is reported after C7B.00.
What is the ICD-9 equivalent of C7B.00?
Under the General Equivalence Mappings, secondary carcinoid tumors, unspecified site converts to ICD-9-CM 209.70 (sec neuroendo tumor NOS). The mapping is approximate, so confirm the match fits the documentation.
What HCC is C7B.00?
C7B.00 (secondary carcinoid tumors, unspecified site) maps to CMS-HCC Category 17 (Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic), commonly written as HCC 17, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2027. It mapped to HCC 8 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. In the Part D prescription drug model it maps to RxHCC 18.
Does C7B.00 risk-adjust for Medicare Advantage payment?
Yes. When documented and reported on a Medicare Advantage encounter, C7B.00 adds a risk adjustment factor of about 4.209 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 1.952 to 4.235 depending on the payment segment). HCC 17 sits at the top of its hierarchy, so no other condition category supersedes it. See the full factor table on the HCC 17 category page.
